3,088
Views
30
CrossRef citations to date
0
Altmetric
Original Article

Pneumonia with empyema among children in the first five years of high coverage with 13-valent pneumococcal conjugate vaccine

, , , , &
Pages 749-753 | Received 29 Jan 2016, Accepted 14 May 2016, Published online: 20 Jun 2016

References

  • Bradley JS, Byington CL, Shah SS, et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis. 2011;53:e25–e76.
  • Light RW. Parapneumonic effusions and empyema. Proc Am Thorac Soc. 2006;3:75–80.
  • Sahn SA. Diagnosis and management of parapneumonic effusions and empyema. Clin Infect Dis. 2007;45:1480–1486.
  • Resti M, Moriondo M, Cortimiglia M, et al. Community‐acquired bacteremic pneumococcal pneumonia in children: diagnosis and serotyping by real‐time polymerase chain reaction using blood samples. Clin Infect Dis. 2010;51:1042–1049.
  • Blaschke AJ, Heyrend C, Byington CL, et al. Molecular analysis improves pathogen identification and epidemiologic study of pediatric parapneumonic empyema. Pediatr Infect Dis J. 2011;30:289–294.
  • Strachan RE, Cornelius A, Gilbert GL, et al. Bacterial causes of empyema in children, Australia, 2007–2009. Emerging Infect Dis. 2011;17:1839–1845.
  • Obando I, Camacho-Lovillo MS, Porras A, et al. Sustained high prevalence of pneumococcal serotype 1 in paediatric parapneumonic empyema in southern Spain from 2005 to 2009. Clin Microbiol Infect. 2012;18:763–768.
  • Lin TY, Hwang KP, Liu CC, et al. Etiology of empyema thoracis and parapneumonic pleural effusion in Taiwanese children and adolescents younger than 18 years of age. Pediatr Infect Dis J. 2013;32:419–421.
  • Jardine A, Menzies RI, McIntyre PB. Reduction in hospitalizations for pneumonia associated with the introduction of a pneumococcal conjugate vaccination schedule without a booster dose in Australia. Pediatr Infect Dis J. 2010;29:607–612.
  • Griffin MR, Zhu Y, Moore MR, et al. U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination. N Engl J Med. 2013;369:155–163.
  • Yu J, Salamon D, Marcon M, et al. Pneumococcal serotypes causing pneumonia with pleural effusion in pediatric patients. J Clin Microbiol. 2011;49:534–538.
  • Picazo J, Ruiz-Contreras J, Casado-Flores J, et al. Expansion of serotype coverage in the universal pediatric vaccination calendar: short-term effects on age- and serotype-dependent incidence of invasive pneumococcal clinical presentations in Madrid, Spain. Clin Vaccine Immunol. 2013;20:1524–1530.
  • Angoulvant F, Levy C, Grimprel E, et al. Early impact of 13-valent pneumococcal conjugate vaccine on community-acquired pneumonia in children. Clin Infect Dis. 2014;58:918–924.
  • Grivea IN, Priftis KN, Giotas A, et al. Dynamics of pneumococcal carriage among day-care center attendees during the transition from the 7-valent to the higher-valent pneumococcal conjugate vaccines in Greece. Vaccine. 2014;32:6513–6520.
  • Xirogianni A, Tsolia M, Voyiatzi A, et al. Diagnosis of upper and lower respiratory tract bacterial infections with the use of multiplex PCR assays. Diagnostics. 2013;3:222–231.
  • Azzari C, Moriondo M, Indolfi G, et al. Realtime PCR is more sensitive than multiplex PCR for diagnosis and serotyping in children with culture negative pneumococcal invasive disease. PLoS One. 2010;19:e9282.
  • Chini V, Petinaki E, Foka A, et al. Spread of Staphylococcus aureus clinical isolates carrying Panton–Valentine leukocidin genes during a 3-year period in Greece. Clin Microbiol Infect. 2006;12:29–34.
  • Yeh SH, Gurtman A, Hurley DC, et al. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers. Pediatrics. 2010;126:e493–e505.
  • Snape MD, Klinger CL, Daniels ED, et al. Immunogenicity and reactogenicity of a 13-valent-pneumococcal conjugate vaccine administered at 2, 4, and 12 months of age: a double-blind randomized active-controlled trial. Pediatr Infect Dis J. 2010;29:e80–e90.
  • Kieninger DM, Kueper K, Steul K, et al. Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany. Vaccine. 2010;28:4192–4203.
  • Esposito S, Tansey S, Thompson A, et al. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers. Clin Vaccine Immunol. 2010;17:1017–1026.
  • Vanderkooi OG, Scheifele DW, Girgenti D, et al. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine pediatric vaccinations in Canada. Pediatr Infect Dis J. 2012;31:72–77.
  • Madhi F, Godot C, Bidet P, et al. Serotype 3 pneumococcal pleural empyema in an immunocompetent child after 13-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2014;33:545–546.
  • Antachopoulos C, Tsolia MN, Tzanakaki G, et al. Parapneumonic pleural effusions caused by Streptococcus pneumoniae serotype 3 in children immunized with 13-valent conjugated pneumococcal vaccine. Pediatr Infect Dis J. 2014;33:81–83.
  • Slinger R, Hyde L, Moldovan I, et al. Direct Streptococcus pneumoniae real-time PCR serotyping from pediatric parapneumonic effusions. BMC Pediatr. 2014;14:189.
  • Ahn JG, Choi SY, Kim DS, et al. Changes in pneumococcal nasopharyngeal colonization among children with respiratory tract infections before and after use of the two new extended-valency pneumococcal conjugated vaccines. Infect Dis. 2015;47:385–392.